The department used its new system for determining whether a condition is service-connected to give affected veterans access ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

The FDA has granted LBL-034 orphan drug designation for relapsed/refractory multiple myeloma treatment. LBL-034 has received ...

In a real-world study involving patients with standard-risk, newly-diagnosed multiple ... death or progression were reported, with 10 occurring in the tandem ASCT group (50%) and 22 occurring in the ...

Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with ...

CARVYKTI demonstrated a 45% reduction in the risk of death compared to standard therapies in multiple myeloma patients ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

SpringWorks to present long-term efficacy and safety data from phase 3 DeFi trial of Ogsiveo in adults with desmoid tumours at CTOS 2024 meeting ...

Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...